{"filing":{"accession_number":"0001493152-26-035626","cik":"0001838716","ticker":"GNTA","company_name":"Genenta Science S.p.A.","form":"6-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1838716/000149315226035626/form6-k.htm"},"events":[{"id":22380,"run_id":20243,"accession_number":"0001493152-26-035626","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The 6-K discloses results of an Extraordinary Shareholders' Meeting held July 29, 2026, where shareholders approved three material proposals: (1) delegation to the Board to increase share capital by up to €300 million and issue up to 120 million new shares and convertible bonds; (2) authorization for a reverse stock split at a 1-for-10 to 1-for-20 ratio to maintain Nasdaq compliance. While a corporate name-change proposal was deferred, the approved resolutions grant significant capital-raising and restructuring authority that would materially affect investors' assessment of dilution risk and the company's financial flexibility.","company_name":"Genenta Science S.p.A.","ticker":"GNTA","filing_date":"2026-07-31","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":22303,"accession_number":"0001493152-26-035626","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The 6-K discloses results of an Extraordinary Shareholders' Meeting held July 29, 2026, where shareholders approved three material proposals: (1) delegation to the Board to increase share capital by up to €300 million and issue up to 120 million new shares and convertible bonds; (2) authorization for a reverse stock split at a 1-for-10 to 1-for-20 ratio to maintain Nasdaq compliance. While a corporate name-change proposal was deferred, the approved resolutions grant significant capital-raising and restructuring authority that would materially affect investors' assessment of dilution risk and the company's financial flexibility.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:10:17.357650+00:00","company_name":"Genenta Science S.p.A.","ticker":"GNTA","filing_date":"2026-07-31"}]}